NCT00174356 - PH 1 Evaluation Of Oral CI-1033 In Combination With Paclitaxel/ Carboplatin As 1st Line Chemotherapy In NSCLC Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 31, 2002

Study Completion Date

October 31, 2005

Conditions

Carcinoma, Non-Small Cell Lung

Interventions

DRUG

CI 1033

DRUG

PACLITAXEL

DRUG

CARBOPLATIN

Trial Locations (7)

Pfizer Investigational Site, Tampa

Pfizer Investigational Site, Louisville

Pfizer Investigational Site, Louisville

Pfizer Investigational Site, Park Ridge

Pfizer Investigational Site, Skokie

Pfizer Investigational Site, Houston

Pfizer Investigational Site, Hamilton